Five NSCLC patients harboring EGFR-sensitizing mutations were excluded from the analysis due to protocol deviation: they received only one cycle of ICIs-based therapy prior to confirmation of their EGFR mutation status, and subsequently transitioned to EGFR-tyrosine kinase inhibitor treatment. Here, EGFR is linked to non-small cell lung carcinoma.